Furthermore, specific antagonists of TLR7,9 and STING, which are in early-phase trials for SLE (70) and various interferonopathies (71), respectively, also show promise for obesity treatment given their therapeutic potency in mouse models of the disease. This evidence concerns the gene STING1 and obesity due to melanocortin 4 receptor deficiency.